EMEA Will Evaluate All NSAIDs In Search Of Potential “Class Effect”
This article was originally published in The Tan Sheet
Executive Summary
The EU health authority will undertake its own review of all non-steroidal anti-inflammatory drugs in light of safety concerns surrounding COX-2 inhibitors